Related Articles
Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S‑1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest
Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy
Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S‑1 adjuvant chemotherapy
Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1
Current status of extended ‘D2 plus’ lymphadenectomy in advanced gastric cancer (Review)